Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LIPO OTCMKTS:OMGAQ NASDAQ:PTIX NASDAQ:WINT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLIPOLipella Pharmaceuticals$0.08-38.5%$0.08$0.02▼$0.94$370K1.3530,258 shs104,203 shsOMGAQOmega Therapeutics$0.00$0.00$0.00▼$1.69$166K0.57215,590 shsN/APTIXAtrinsic$0.22-3.5%$0.54$0.20▼$6.20$402K1.0132,976 shs2,528 shsWINTWindtree Therapeutics$0.02+6.3%$0.02$0.01▼$1.86$765K1.55310,871 shs140,366 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLIPOLipella Pharmaceuticals-38.46%+37.93%-23.81%+261.99%-89.74%OMGAQOmega Therapeutics0.00%0.00%0.00%0.00%-97.60%PTIXAtrinsic-3.52%-43.41%-55.62%-58.13%-93.46%WINTWindtree Therapeutics+6.25%+13.33%+18.06%+54.55%-98.11%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLIPOLipella Pharmaceuticals$0.08-38.5%$0.08$0.02▼$0.94$370K1.3530,258 shs104,203 shsOMGAQOmega Therapeutics$0.00$0.00$0.00▼$1.69$166K0.57215,590 shsN/APTIXAtrinsic$0.22-3.5%$0.54$0.20▼$6.20$402K1.0132,976 shs2,528 shsWINTWindtree Therapeutics$0.02+6.3%$0.02$0.01▼$1.86$765K1.55310,871 shs140,366 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLIPOLipella Pharmaceuticals-38.46%+37.93%-23.81%+261.99%-89.74%OMGAQOmega Therapeutics0.00%0.00%0.00%0.00%-97.60%PTIXAtrinsic-3.52%-43.41%-55.62%-58.13%-93.46%WINTWindtree Therapeutics+6.25%+13.33%+18.06%+54.55%-98.11%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLIPOLipella Pharmaceuticals 0.00N/AN/AN/AOMGAQOmega Therapeutics 0.00N/AN/AN/APTIXAtrinsic 1.00SellN/AN/AWINTWindtree Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLIPOLipella Pharmaceuticals$536.36K0.69N/AN/A$1.59 per share0.05OMGAQOmega Therapeutics$3.09M0.05N/AN/A$1.05 per share0.00PTIXAtrinsicN/AN/AN/AN/A$1.96 per shareN/AWINTWindtree TherapeuticsN/AN/AN/AN/A$0.98 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLIPOLipella Pharmaceuticals-$5.02M-$2.42N/AN/AN/A-988.83%-224.08%-172.88%9/2/2026 (Estimated)OMGAQOmega Therapeutics-$97.43M-$1.33N/AN/AN/AN/AN/AN/AN/APTIXAtrinsic-$5.53M-$3.45N/AN/AN/AN/AN/A-379.72%N/AWINTWindtree Therapeutics-$1.79M-$8.77N/AN/AN/AN/A-207.34%-50.19%8/19/2026 (Estimated)Compare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthLIPOLipella PharmaceuticalsN/AN/AN/AN/AN/AOMGAQOmega TherapeuticsN/AN/AN/AN/AN/APTIXAtrinsicN/AN/AN/AN/AN/AWINTWindtree TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLIPOLipella PharmaceuticalsN/A6.216.21OMGAQOmega TherapeuticsN/AN/AN/APTIXAtrinsicN/A0.290.29WINTWindtree TherapeuticsN/A0.430.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLIPOLipella Pharmaceuticals74.31%OMGAQOmega Therapeutics97.47%PTIXAtrinsic7.97%WINTWindtree Therapeutics29.33%Insider OwnershipCompanyInsider OwnershipLIPOLipella Pharmaceuticals32.11%OMGAQOmega Therapeutics8.50%PTIXAtrinsic8.00%WINTWindtree Therapeutics0.15%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLIPOLipella Pharmaceuticals44.62 million3.03 millionNot OptionableOMGAQOmega Therapeutics12055.37 million50.66 millionOptionablePTIXAtrinsic21.81 million1.78 millionNot OptionableWINTWindtree Therapeutics3044.99 million3.66 millionNot OptionableOMGAQ, WINT, PTIX, and LIPO HeadlinesRecent News About These CompaniesWindtree Therapeutics Delays Filing of Annual ReportApril 1, 2026 | tipranks.comCommLoan Achieves Nationwide Regulatory Approval Across All 50 StatesMarch 17, 2026 | prnewswire.comWindtree Therapeutics Announces Sudden Departure of President and COOJanuary 17, 2026 | theglobeandmail.comWindtree sells heart drug assets, keeps a cut of any future breakthroughDecember 30, 2025 | msn.comWindtree Therapeutics Announces the Sale of its Cardiovascular Biotech Pipeline Drug CandidatesDecember 23, 2025 | finance.yahoo.comWindtree Therapeutics Announces It Has Signed a Letter of Intent to Acquire CommLoan, Inc. a Revenue Generating Company in the Rapidly Growing Fintech SpaceDecember 4, 2025 | markets.businessinsider.comWindtree announces it has signed a letter of intent to acquire CommLoanDecember 4, 2025 | msn.comWindtree Expands Global Patent Portfolio as Heart Failure Pipeline Gains MomentumNovember 20, 2025 | msn.comWindtree may receive license agreement payments for renewed development workNovember 17, 2025 | msn.comWindtree Therapeutics Announces It May Receive License Agreement Payments from Its Licensee for Renewed Acute Pulmonary Development by the LicenseeNovember 17, 2025 | finance.yahoo.comWindtree Therapeutics announces patents allowed in Canada, MexicoNovember 14, 2025 | msn.comWindtree Therapeutics Announces More Strengthening of Its Istaroxime and Next Generation SERCA2a activator Patent EstateNovember 14, 2025 | markets.businessinsider.comWindtree Therapeutics Delays Quarterly Report FilingNovember 14, 2025 | tipranks.comWindtree Therapeutics Signs Letter of Intent with TESI for $7.5 Million Cash and Securities AgreementNovember 13, 2025 | quiverquant.comQWindtree Therapeutics Announces It Will Receive $7.5 Million In Cash and Securities from the Recently Executed Termination Agreement with an Environmental Services CompanyNovember 13, 2025 | globenewswire.comWindtree Therapeutics Announces It Will Receive $7.5 Million In Cash and Securities from the Recently Executed Termination Agreement with an Environmental Services CompanyNovember 13, 2025 | globenewswire.comWindtree Therapeutics Approves Key Financial Structure ChangesSeptember 3, 2025 | msn.comWindtree Therapeutics Stockholders Approve Key Proposals for Revenue and Profit Generation at the Special Stockholder MeetingSeptember 2, 2025 | markets.businessinsider.comWindtree Therapeutics, Inc. Stockholders Approve Strategic Shift Toward Environmental Services and Biotech PartnershipsSeptember 2, 2025 | quiverquant.comQWarrington’s Windtree Therapeutics Faces Uncertain Future After NASDAQ DelistingAugust 27, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMission Control: Floating In SpaceX's Record-Breaking OrbitBy Jeffrey Neal Johnson | June 15, 2026SpaceX Rings the Bell and Shatters Every RecordBy Jeffrey Neal Johnson | June 12, 2026Gravity Check: Houston, SpaceX Has a Valuation ProblemBy Jeffrey Neal Johnson | June 16, 2026Crypto Winter Is Here: 3 Stocks To Put On Ice This SummerBy Dan Schmidt | June 9, 2026Summer Is Coming–But There's No End in Sight for This Crypto WinterBy Jessica Mitacek | June 15, 2026OMGAQ, WINT, PTIX, and LIPO Company DescriptionsLipella Pharmaceuticals NASDAQ:LIPO$0.08 -0.05 (-38.46%) As of 07/6/2026 11:44 AM EasternLipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.Omega Therapeutics OTCMKTS:OMGAQ$0.0030 0.00 (0.00%) As of 07/2/2026Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.Atrinsic NASDAQ:PTIX$0.22 -0.01 (-3.52%) As of 07/6/2026 12:36 PM EasternProtagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.Windtree Therapeutics NASDAQ:WINT$0.02 +0.00 (+6.25%) As of 07/6/2026 01:49 PM EasternWindtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. In addition, it is developing aPKCi Inhibitor for the treatment of cutaneous malignancies and solid tumors that is in preclinical trials. Windtree Therapeutics, Inc. has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; license, development and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Flash Crash or Cash? The AI Hardware Reset Investors Can’t Ignore KBR Insiders Are Buying While the Market Misreads Its Spinoff Doug Casey Calls AI a Super Bubble, Bets on Energy, Gold Miners and Grains Contrarian Alert: 5 Downgraded Stocks That May Reward Long-Term Investors This Edge AI Stock Just Got a Huge Vote of Confidence From Wall Street AI Is Selling Off, But These 5 Stocks Could Benefit Next MarketBeat Week in Review – 06/29 - 07/03 Analysts Just Raised Price Targets On These 3 Semiconductor Equipment Stocks Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
